Document is current
Any future updates will be listed below
-
Authors
Lees, Ty https://orcid.org/0000-0002-7321-2704
Scott, Jason N. Jr
Boyle, Brian W.
Esfand, Shiba M.
Linton, Samantha R.
Miller, Courtney
Li, Mohan https://orcid.org/0009-0008-6615-8077
Woronko, Sarah E. https://orcid.org/0000-0001-6517-4106
Dunayev, Rebecca
Bogdanov, Mario https://orcid.org/0000-0003-2386-3557
Bolton, Paula
Li, Shuang
Meisner, Robert C.
Pizzagalli, Diego A. https://orcid.org/0000-0002-7772-1143
-
Funding
Funding for this research was provided by:
Funding for this project was provided by an investigator-initiated contract from Millennium Pharmaceuticals (awarded to D.A.P).
- License Information
-
More Information
Article History
Received: 8 August 2025
Revised: 17 February 2026
Accepted: 20 February 2026
First Online: 6 March 2026
Competing interests
: Over the past 3 years, Dr. Pizzagalli has received consulting fees from Abbvie, Arrowhead Pharmaceuticals, Boehringer Ingelheim, Circular Genomics, Compass Pathways, Engrail Therapeutics, N1 Biocorp Inc, Neumora Therapeutics, Neurocrine Biosciences, Neuroscience Software, Takeda, TP Sciences, and Xenon Pharmaceuticals; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) and Alkermes; he has received research funding from the Bird Foundation, Brain and Behavior Research Foundation, Circular Genomics, Dana Foundation, Millennium Pharmaceuticals, NIMH, and Wellcome Leap; he has received stock options from Ceretype Neuromedicine, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. All other authors have no conflicts of interest or relevant disclosures. All views expressed are solely those of the authors.
